Efficacy and safety of novel carbapenem-β-lactamase inhibitor combinations: imipenem-cilastatin/relebactam results from randomized controlled trials

BackgroundGram-negative bacteria is a global public health problem. Treatment options include novel beta-lactamase inhibitors.ObjectivesThe objective of this study was to collect information on the efficacy and safety of novel β-lactamase inhibitor combinations such as imipenem-cilastatin/relebactam...

Full description

Bibliographic Details

Published in:	Frontiers in Medicine
Main Authors:	Qingxin Yang, Yanqiu Yang, Rong He, Bin Yu, Yueling Zhong, Fei Lin
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2023-12-01
Subjects:	imipenem/cilastatin/relebactam novel carbapenem-β-lactamase inhibitor combination efficacy safety bacterial infections
Online Access:	https://www.frontiersin.org/articles/10.3389/fmed.2023.1304369/full